Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-18
DOI
10.1007/s11523-019-00665-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Hyun Cheol Chung et al. Journal for ImmunoTherapy of Cancer
- Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
- (2019) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
- (2018) Matthew D. Galsky et al. EUROPEAN UROLOGY
- Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
- (2018) Lívia Rojkó et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
- (2018) Robert M. Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
- (2018) Amit M Oza et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
- (2018) Justin Yeh et al. Journal of Thoracic Disease
- Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.
- (2018) Marleen Kok et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
- (2018) Greg Andrew Durm et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).
- (2018) Xiao X. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
- (2018) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with
- (2018) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
- (2017) T. Mok et al. Journal of Thoracic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer
- (2016) Orhan Onder Eren et al. AMERICAN JOURNAL OF THERAPEUTICS
- A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
- (2016) T. Powles et al. ANNALS OF ONCOLOGY
- 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
- (2016) K. Nakagawa et al. ANNALS OF ONCOLOGY
- Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
- (2016) H. Y. Luo et al. ANNALS OF ONCOLOGY
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
- (2016) Chrisann Kyi et al. Immunotherapy
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma
- (2016) Zhengbo Song et al. LUNG CANCER
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of Life and Mortality of Long-Term Colorectal Cancer Survivors in the Seattle Colorectal Cancer Family Registry
- (2016) Scott V. Adams et al. PLoS One
- Cancer immunotherapy targeting neoantigens
- (2016) Yong-Chen Lu et al. SEMINARS IN IMMUNOLOGY
- Withdrawal of anticancer therapy in advanced disease: a systematic literature review
- (2015) G. Clarke et al. BMC CANCER
- Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy
- (2015) Helen HW Chen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Design Issues in Randomized Clinical Trials of Maintenance Therapies
- (2015) Boris Freidlin et al. JNCI-Journal of the National Cancer Institute
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design Issues in Randomized Clinical Trials of Maintenance Therapies
- (2015) Boris Freidlin et al. JNCI-Journal of the National Cancer Institute
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
- (2015) Bryan Oronsky et al. NEOPLASIA
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
- (2013) V. Polo et al. ANNALS OF ONCOLOGY
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
- (2013) Petros D. Grivas et al. CANCER
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
- (2013) David E. Gerber et al. JOURNAL OF CLINICAL ONCOLOGY
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
- (2013) Giuseppe Tonini et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Cesare Gridelli et al. Journal of Thoracic Oncology
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- (2012) Luis Paz-Ares et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
- (2010) N. Thatcher et al. ONCOLOGIST
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review: Advanced non-small cell lung cancer: the role of maintenance therapy
- (2009) Anuj K. Agarwala et al. Therapeutic Advances in Medical Oncology
- The anticancer immune response: indispensable for therapeutic success?
- (2008) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now